Imatinib Mesylate is orally bioavailability mesylate salt of Imatinib, which is a multi-target inhibitor of v-Abl, c-Kit and PDGFR with IC50 of 0.6 µM, 0.1 µM and 0.1 µM, respectively. Imatinib is currently being investigated in Phase III clinical trials
CAS Number:
[220127-57-1]
Application Notes:
BCK
* VAT and and shipping costs not included. Errors and price changes excepted